Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons: A Randomized, Placebo-Controlled TrialReport as inadecuate




Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons: A Randomized, Placebo-Controlled Trial - Download this document for free, or read online. Document in PDF available to download.

Background

Untreated HIV may increase the risk of cardiovascular events. Our preliminary in vitro and in vivo research suggests that pentoxifylline PTX reduces vascular inflammation and improves endothelial function in HIV-infected persons not requiring antiretroviral therapy.

Methods

We performed a randomized, placebo-controlled trial of PTX 400 mg orally thrice daily for 8 weeks in 26 participants. The primary endpoint was change in flow-mediated dilation FMD of the brachial artery after 8 weeks. Nitroglycerin-mediated dilation NTGMD and circulating markers of inflammation, cellular immune activation, coagulation, and metabolism were also assessed.

Results

The difference in mean absolute change SD in FMD after 8 weeks between the placebo −1.06 1.45% and PTX −1.93 3.03% groups was not significant P = 0.44. No differences in NTGMD were observed. The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 sTNFRI −83.2 pg-mL in the placebo group vs. +65.9 pg-mL in the PTX group; P = 0.03. PTX was generally well-tolerated.

Conclusions

PTX did not improve endothelial function and unexpectedly increased the inflammatory biomarker sTNFRI in HIV-infected participants not requiring antiretroviral therapy. Additional interventional research is needed to reduce inflammation and cardiovascular risk in this population.

Trial Registration

ClinicalTrials.gov NCT00796822



Author: Samir K. Gupta , Deming Mi, Michael P. Dubé, Chandan K. Saha, Raymond M. Johnson, James H. Stein, Matthias A. Clauss, Kieren J.

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents